Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyVoriconazole therapeutic drug monitoring.Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosisIn vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelApplication of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionDose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsOnce-daily cefazolin and probenecid for skin and soft tissue infectionsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemEradication by ceftriaxone of Streptococcus pneumoniae isolates with increased resistance to penicillin in cases of acute otitis mediaChairman's introduction--the importance of good quality surveillance data today.Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronicComparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.Cotrimoxazole - optimal dosing in the critically ill.Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media.In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media.In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance.In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionManagement of infections due to antibiotic-resistant Streptococcus pneumoniaeLimiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniaeSusceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance studyCharacterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young childrenIn vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin.Optimal dose of amoxicillin in treatment of otitis media caused by a penicillin-resistant pneumococcus strain in the gerbil model.Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.In vivo pharmacodynamics of a new oxazolidinone (linezolid)Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensStaphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocolsPharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside.
P2860
Q24519008-DEAA4396-B638-49F8-8316-B42DEF76B5ABQ24542411-A10EAEF5-B573-430A-B684-070E56AF6755Q24651516-0360AD26-9482-45DD-9B75-A961B866C660Q24654780-8699A8F0-7C08-47EA-B442-842DB70C3CBDQ26753831-F12A8C53-444F-40E4-8E2F-4C37877466E9Q26853629-BBEBB355-FA5D-496C-BEE1-20DF754E8D54Q28245769-F883DB12-4903-4236-A22F-9E9F4965FC63Q28289744-90DB85E0-A4A0-43AB-A47E-AF3C5D5CB759Q28369448-286B41AA-0362-4F01-91BF-7C2181D0B4B0Q30573318-542ECC23-4206-4188-9248-5A10833A807FQ33541485-88659D12-7FA0-4776-9F10-E0BC96469347Q33556653-9B2856D4-C5C1-41F7-9919-68542FC42AC4Q33613654-F70724F9-386C-4F92-8C67-AD355E7A3F7DQ33652427-A41F6045-A5DC-4180-A189-8167D41B8EADQ33691073-6088D0CF-DD70-4A30-803B-A5C27FD7928EQ33693273-20E47EEB-8202-441D-B674-E68E0EF6B2B6Q33694789-FD77C58F-0E7C-4DF2-B450-E3701443CA5AQ33697003-4D174DC9-CB78-4D74-A5F1-8BAC1C236D4FQ33703410-47DD3FD8-B118-4FF2-B840-0447B06E3C3EQ33784516-4D5461D6-2987-4C57-B43C-0589FCA6E174Q33797936-1CCFF3C4-147C-46BD-BA46-C09DCBBE40C5Q33975374-18318724-FAEE-40E5-8846-D63AE008455AQ33975560-994B2531-24D7-40ED-AA42-91F58F6EA8E2Q33975832-38F46F9C-8F25-4DA6-B18B-A52CC054880CQ33977347-231F7D25-019B-4283-A6F1-D689F2C1B1B1Q33977551-AFCA44FD-B4F6-4CBF-AAF4-B38F7C0B985FQ33978422-51636BA9-90DE-44EB-871E-5134F5B9D5B7Q33979115-72025487-B57D-448A-B075-7CF6F5030F55Q33979445-7963AA35-8077-4C35-B311-144970BA14BAQ33982991-A10BDA3E-0142-4398-BBAA-EA384BBBC941Q34045319-6CA55119-768A-40A5-910B-660B26BF2F65Q34077003-1160B911-A820-47BA-9CD6-4C048E34983CQ34110986-DFFB0EAD-80A7-4CDB-BD48-52A813759236Q34113560-DFC77382-04B2-4BCF-9A8E-3BEE3C51D0CBQ34139332-7DF119DA-187A-4BE5-B2F5-14BD8F5B7805Q34142754-CAA0B7A0-4136-4540-BFDD-AB4C747CD244Q34274190-5724CB2D-4A7D-453E-85D2-86CA0B801FD7Q34381321-D63D1B9F-C88A-4B83-AF56-B61E95F58C85Q34387384-759ADD96-4ECB-4041-A321-15B60D8C09A8Q34443415-C5A8BDAB-20DB-4285-91B8-781618EBEE7D
P2860
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
@en
type
label
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
@en
prefLabel
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
@en
P1476
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
@en
P2093
P304
P356
10.1097/00006454-199603000-00015
P577
1996-03-01T00:00:00Z